Articles related to CHEMOTHERAPY

Final analysis confirms venetoclax plus modified intensive chemotherapy achieves durable remissions with 17.9-month treatment-free intervals in fit elderly AML patients, particularly those with de novo disease.

Experts note that the use of chemotherapy can indicate cancer spread beyond its origin, potentially reflecting the stage, aggressiveness, or progression potential of the disease.

Recent research from Brown University suggests that the SARS-CoV-2 spike protein could interfere with cancer treatment efficacy by affecting the p53 gene’s ability to suppress tumor growth and repair DNA.

Explore new horizons in advanced hepatocellular carcinoma treatment with emerging data on lenvatinib and cisplatin’s potential efficacy as a second-line therapy and the promising triple combination therapy showing significant response rates.

Explore key points for patient communication on chemotherapy, offering a clear framework to discuss treatment goals, processes, and side effects, enhancing patient understanding and engagement in their care journey.

In a recent phase 3 trial, a low-dose chemotherapy regimen demonstrated noninferior efficacy to standard-dose regimens in pediatric AML patients, while significantly reducing non-hematologic toxicities, an important consideration in pediatric oncology.